Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Vija Skripconoka,Manfred Danilovits,Lea Pehme,Tarmo Tomson,Girts Skenders,Tiina Kummik,Andra Cirule,Vaira Leimane,Anu Kurve,Klavdia Levina,Lawrence Geiter,Davide Manissero,Charles D. Wells +12 more
TLDR
It is suggested that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.Abstract:
Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease. Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes. Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable. Delamanid treatment groups were combined for analysis, based on their duration of treatment. In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments. Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months. Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001). Treatment benefit was also seen among patients with extensively drug-resistant TB. This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.read more
Citations
More filters
Journal ArticleDOI
Advances in the development of new tuberculosis drugs and treatment regimens
TL;DR: Current concepts and recent advances in TB drug discovery and development are covered, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.
Journal ArticleDOI
Towards tuberculosis elimination: an action framework for low-incidence countries
Knut Lönnroth,Giovanni Battista Migliori,Ibrahim Abubakar,Lia D'Ambrosio,Gerard De Vries,Roland Diel,Paul Douglas,Dennis Falzon,Marc Andre Gaudreau,Delia Goletti,Edilberto R. González Ochoa,Philip A. LoBue,Alberto Matteelli,Howard Njoo,Ivan Solovic,Alistair Story,Tamara Tayeb,Marieke J. van der Werf,Diana Weil,Jean-Pierre Zellweger,Mohamed Abdel Aziz,Mohamed R.M. Al Lawati,Stefano Aliberti,Wouter Arrazola de Oñate,Draurio Barreira,Vineet Bhatia,Francesco Blasi,Amy Bloom,Judith Bruchfeld,Francesco Castelli,Rosella Centis,Daniel Chemtob,Daniela Maria Cirillo,Alberto Colorado,Andrei Dadu,Ulf R Dahle,Laura De Paoli,Hannah Monica Yesudian Dias,Raquel Duarte,Lanfranco Fattorini,Mina Gaga,Haileyesus Getahun,Philippe Glaziou,Lasha Goguadze,Mirtha del Granado,Walter Haas,Asko Järvinen,Geun Yong Kwon,Davide Mosca,Payam Nahid,Nobuyuki Nishikiori,I. Noguer,Joan O'Donnell,Analita Pace-Asciak,Maria Grazia Pompa,Gilda Popescu,Carlos Robalo Cordeiro,Karin Rønning,Morten Ruhwald,Jean-Paul Sculier,Aleksandar Simunovic,Alison Smith-Palmer,Giovanni Sotgiu,Giorgia Sulis,Carlos A. Torres-Duque,Kazunori Umeki,Mukund Uplekar,Catharina Van Weezenbeek,Tuula Vasankari,Robert J. Vitillo,Constantia Voniatis,Maryse Wanlin,Mario C. Raviglione +72 more
TL;DR: An action framework for countries with low tuberculosis (TB) incidence sets out priority interventions required for these countries to progress first towards “pre-elimination” and eventually the elimination of TB as a public health problem.
Journal ArticleDOI
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Keertan Dheda,Tawanda Gumbo,Gary Maartens,Kelly E. Dooley,Ruth McNerney,Megan Murray,Jennifer Furin,Edward A. Nardell,Leslie London,Erica Lessem,Grant Theron,Paul D. van Helden,Stefan Niemann,Matthias Merker,David W. Dowdy,Annelies Van Rie,Annelies Van Rie,Gilman Kit Hang Siu,Jotam G. Pasipanodya,Camilla Rodrigues,Taane G. Clark,F. A. Sirgel,Aliasgar Esmail,Hsien-Ho Lin,Sachin R Atre,H. Simon Schaaf,Kwok Chiu Chang,Christoph Lange,Payam Nahid,Zarir F Udwadia,C. Robert Horsburgh,Gavin J. Churchyard,Gavin J. Churchyard,Dick Menzies,Anneke C. Hesseling,Eric L. Nuermberger,Helen McIlleron,Kevin P. Fennelly,Eric Goemaere,Ernesto Jaramillo,Marcus Low,Carolina Morán Jara,Nesri Padayatchi,Robin M. Warren +43 more
TL;DR: Several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis.
Journal ArticleDOI
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Alimuddin Zumla,Alimuddin Zumla,Stephen H. Gillespie,Michael Hoelscher,Patrick P J Philips,Stewart T. Cole,Ibrahim Abubakar,Timothy D. McHugh,Marco Schito,Markus Maeurer,Andrew J. Nunn +10 more
TL;DR: The need to engage the community in design, implementation, and uptake of research is emphasised, to increase international cooperation between drug developers and health-care providers adopting new regimens.
Journal ArticleDOI
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Christoph Lange,Ibrahim Abubakar,Jan-Willem C. Alffenaar,Graham H. Bothamley,Jose A. Caminero,Anna Cristina Calçada Carvalho,Kwok Chiu Chang,Luigi Codecasa,Ana Maria Correia,Valeriu Crudu,Peter Davies,Martin Dedicoat,Francis Drobniewski,Raquel Duarte,Cordula Ehlers,Connie Erkens,Delia Goletti,Gunar Günther,Elmira Ibraim,Beate Kampmann,Liga Kuksa,Wiel C M de Lange,Frank van Leth,Jan Van Lunzen,Alberto Matteelli,Dick Menzies,Ignacio Monedero,Elvira Richter,Sabine Rüsch-Gerdes,Andreas Sandgren,Anna Scardigli,Alena Skrahina,Enrico Tortoli,Grigory V. Volchenkov,Dirk Wagner,Marieke J. van der Werf,Bhanu Williams,Wing Wai Yew,Jean-Pierre Zellweger,Daniela Maria Cirillo +39 more
TL;DR: This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
References
More filters
Book ChapterDOI
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
TL;DR: Comparing the socialist nature of many European counties, there is a requirement that provision be made for patients to be made whole regardless of the outcomes of the trial or if they happened to have been randomized to a control group that did not enjoy the benefits of a successful experimental intervention.
Journal Article
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.
TL;DR: The Helsinki Declaration on Ethical Principles for Medical Research Involving Human Subjects, adopted by the World Medical Assembly, is presented.
Journal ArticleDOI
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Neel R. Gandhi,Neel R. Gandhi,Anthony P. Moll,A. Willem Sturm,Robert Pawinski,Thiloshini Govender,Umesh G. Lalloo,Kimberly Zeller,Kimberly Zeller,Jason R. Andrews,Gerald Friedland +10 more
TL;DR: MDR tuberculosis is more prevalent than previously realised in a rural area in KwaZulu Natal, South Africa and has been transmitted to HIV co-infected patients and is associated with high mortality.
Journal ArticleDOI
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Dennis Falzon,Ernesto Jaramillo,Holger J. Schünemann,Matthew Arentz,Melissa Bauer,Jaime Bayona,Léopold Blanc,Jose A. Caminero,Charles L. Daley,Chris Duncombe,Christopher Fitzpatrick,Agnes Gebhard,Haileyesus Getahun,Myriam Henkens,Timothy H. Holtz,J. Keravec,S. Keshavjee,Aamir J. Khan,R. Kulier,Vaira Leimane,Christian Lienhardt,Chunling Lu,Mar'iandyshev Ao,Giovanni Battista Migliori,Fuad Mirzayev,Carole D. Mitnick,Paul Nunn,G. Nwagboniwe,Olivia Oxlade,Domingo Palmero,Patricia B Pavlinac,M. I. D. Quelapio,Mario C. Raviglione,Michael Rich,S. Royce,Sabine Rüsch-Gerdes,A. Salakaia,R. Sarin,Delphine Sculier,Francis Varaine,Marco Vitoria,Judd L. Walson,Fraser Wares,Karin Weyer,Richard A. White,Matteo Zignol +45 more
TL;DR: The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens and systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation.
Journal ArticleDOI
OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice
Makoto Matsumoto,Hiroyuki Hashizume,Tatsuo Tomishige,Masanori Kawasaki,Hidetsugu Tsubouchi,Hirofumi Sasaki,Yoshihiko Shimokawa,Makoto Komatsu +7 more
TL;DR: OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment and is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB.
Related Papers (5)
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler,Vija Skripconoka,Epifanio Sanchez-Garavito,Heping Xiao,Jose L. Cabrera-Rivero,Dante E. Vargas-Vasquez,Mengqiu Gao,Mohamed A. Awad,Seung Kyu Park,Tae Sun Shim,Gee Young Suh,Manfred Danilovits,Hideo Ogata,Anu Kurve,Joon Chang,Katsuhiro Suzuki,Thelma E. Tupasi,Won-Jung Koh,Barbara J. Seaworth,Lawrence Geiter,Charles D. Wells +20 more
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Myungsun Lee,Jongmin Lee,Matthew W. Carroll,Hongjo Choi,Seonyeong Min,Taeksun Song,Laura E. Via,Lisa C. Goldfeder,Eunhwa Kang,Boyoung Jin,Hyeeun Park,Hyun-Kyung Kwak,Hyun-Chul Kim,Han Seung Jeon,Ina Jeong,Joon Sung Joh,Ray Y. Chen,Kenneth N. Olivier,Pamela A. Shaw,Dean Follmann,Sun Dae Song,Jong Koo Lee,Duk-Hyoung Lee,Cheon Tae Kim,Véronique Dartois,Seung-kyu Park,Sang Nae Cho,Clifton E. Barry +27 more
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
Andreas H. Diacon,Alexander S. Pym,Martin P. Grobusch,R. F. Patientia,Roxana Rustomjee,Liesl Page-Shipp,Christoffel Pistorius,Rene Krause,Mampedi Bogoshi,Gavin J. Churchyard,Amour Venter,Jenny Allen,Juan Carlos Palomino,Tine De Marez,Rolf van Heeswijk,Nacer Lounis,Paul Meyvisch,Johan Verbeeck,Wim Parys,Karel de Beule,Koen Andries,David F Mc Neeley +21 more